The Amyloidosis Research Consortium is a nonprofit accelerating the development of and access to new and innovative treatments. We are driving the research that will have the greatest impact on length and quality of life for patients.
Latest news from ARC
Nobel Prize-Winning Science applied to ATTR Amyloidosis
A groundbreaking study in ATTR amyloidosis, using novel CRISPR/Cas9, has dosed the first patient in the UK. This revolutionary technology brings us a step closer to the dream of curing inherited diseases like hereditary amyloidosis.
Amyloidosis Forum launches series meetings on novel endpoints and clinical trial design
The Amyloidosis Forum has launched a series of virtual meetings to focus on Novel Endpoints and Analyses for Clinical Trials in AL amyloidosis. The first meeting of the series took place on October 15th, 2020. The meeting was held in a virtual format and consisted of presentations and panel discussions.
My Amyloidosis Pathfinder
MAP is a free, easy-to-use tool that captures your treatment preferences, goals, and challenges so you can effectively communicate with your amyloidosis care teams. You can also find and compare specialty treatment centers and receive personalized matches to clinical trials.Get Started